Keyur Patel

Journal Article Curr Opin Gastroenterol · May 1, 2024 PURPOSE OF REVIEW: The result of ongoing liver injury - and disease, regardless of cause - is fibrosis, and fibrosis appears to be a critically important result of ongoing injury. Further, in a number of different liver diseases, the presence of fibrosis h ... Full text Link to item Cite

Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.

Journal Article Hepatology · March 15, 2024 BACKGROUND AND AIMS: Blood-based biomarkers have been proposed as an alternative to liver biopsy for noninvasive liver disease assessment in chronic liver disease. Our aims for this systematic review were to evaluate the diagnostic utility of selected bloo ... Full text Link to item Cite

Noninvasive liver disease assessment to identify portal hypertension: Systematic and narrative reviews supporting the AASLD Practice Guideline.

Journal Article Hepatology · March 15, 2024 BACKGROUND AND AIMS: Portal hypertension is a serious complication of cirrhosis, which leads to life-threatening complications. HVPG, a surrogate of portal pressure, is the reference standard test to assess the severity of portal hypertension. However, sin ... Full text Link to item Cite

AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.

Journal Article Hepatology · March 15, 2024 Full text Link to item Cite

AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.

Journal Article Hepatology · March 15, 2024 Full text Link to item Cite

AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension.

Journal Article Hepatology · March 15, 2024 Full text Link to item Cite

Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients

Journal Article Journal of Clinical Medicine · February 1, 2024 The aim of this review is to provide updated information on the clinical use of non-invasive serum and imaging-based tests for fibrosis assessment in chronic hepatitis B (CHB) virus infection. In recent years, non-invasive tests (NIT) have been increasingl ... Full text Cite

Predictors of early and long-term readmissions and their association with survival after liver transplantation

Journal Article Journal of Liver Transplantation · February 1, 2024 Background: The impact of post liver transplantation (LT) readmissions on mortality has not been well described. Thus, the primary objective of our study was to determine predictors of readmissions post-LT and assess impact on survival. Methods: Single cen ... Full text Cite

Acyl-CoA Thioesterase 1 Contributes to Transition of Steatosis to Metabolic-Associated Steatohepatitis

Journal Article International Journal of Hepatology · January 1, 2024 Background. Metabolic dysfunction-associated steatohepatitis (MASH) has become the leading cause of chronic liver disease, but there has been no approved pharmacotherapy to date. Methods. We used a network analysis approach to delineate protein-protein int ... Full text Cite

Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis B.

Journal Article Clin Gastroenterol Hepatol · November 2023 BACKGROUND & AIMS: Patients with chronic hepatitis B (CHB) are at increased risk of hepatocellular carcinoma and (liver-related) mortality. In addition to hepatitis B-related factors, metabolic comorbidities may contribute to the progression of fibrosis. T ... Full text Link to item Cite

A Comprehensive Review of Liver Allograft Fibrosis and Steatosis: From Cause to Diagnosis

Journal Article Transplantation Direct · October 16, 2023 Despite advances in posttransplant care, long-term outcomes for liver transplant recipients remain unchanged. Approximately 25% of recipients will advance to graft cirrhosis and require retransplantation. Graft fibrosis progresses in the context of de novo ... Full text Cite

Availability of living donor optimizes timing of liver transplant in high-risk waitlisted cirrhosis patients.

Journal Article Aging (Albany NY) · September 2, 2023 Liver transplant (LT) candidates have become older and frailer, with growing Non-alcoholic steatohepatitis (NASH) and comorbid disease burden in recent years, predisposing them for poor waitlist outcomes. We aimed to evaluate the impact of access to living ... Full text Link to item Cite

Impact of living donor liver transplantation on long-term cardiometabolic and graft outcomes in cirrhosis due to nonalcoholic steatohepatitis.

Journal Article Clin Transplant · September 2023 BACKGROUND AND AIM: Non-alcoholic steatohepatitis (NASH) is a leading indication for liver transplantation (LT). This study aimed to determine whether living donor LT (LDLT) recipients experienced less recurrent NASH, cirrhosis, and cardiometabolic complic ... Full text Link to item Cite

Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis.

Journal Article Hepatol Commun · August 1, 2023 BACKGROUND: Liver transplantation (LT) is frequently lifesaving for people living with primary sclerosing cholangitis (PSC). However, patients are waitlisted for LT according to the model for end-stage liver disease-sodium (MELD-Na) score, which may not ac ... Full text Link to item Cite

Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.

Journal Article Am J Gastroenterol · July 1, 2023 INTRODUCTION: Hepatitis B surface antigen (HBsAg) loss is associated with improved long-term outcomes of patients with chronic hepatitis B but is infrequently achieved with current monotherapies. We assessed whether combination strategies that included tre ... Full text Link to item Cite

A deep learning framework for personalised dynamic diagnosis of graft fibrosis after liver transplantation: a retrospective, single Canadian centre, longitudinal study.

Journal Article Lancet Digit Health · July 2023 BACKGROUND: Recurrent graft fibrosis after liver transplantation can threaten both graft and patient survival. Therefore, early detection of fibrosis is essential to avoid disease progression and the need for retransplantation. Non-invasive blood-based bio ... Full text Link to item Cite

Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease.

Journal Article J Gastroenterol Hepatol · June 2023 BACKGROUND AND AIM: Staining for hepatitis B viral antigens is often done in liver biopsies from patients with chronic hepatitis B, but its correlates with clinical phenotypes are not well described. METHODS: Biopsies were collected from a large cohort of ... Full text Link to item Cite

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease

Journal Article JHEP Reports · June 1, 2023 Background & Aims: Fibroblast activity is a key feature of fibrosis progression and organ function loss, leading to liver-related complications and mortality. The fibrogenesis marker, PRO-C3, has been shown to have prognostic significance in relation to fi ... Full text Cite

Safety and yield of percutaneous liver biopsy in adults and children with chronic hepatitis B: Results from a prospective, multicenter study.

Journal Article Hepatol Commun · June 1, 2023 BACKGROUND: Prospective data regarding the safety and yield of liver biopsy in both adults and children with chronic hepatitis B are limited. The aim of this study is to report safety, yield, and complication rates among adults and children with chronic he ... Full text Link to item Cite

IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.

Journal Article Hepatology · January 1, 2023 BACKGROUND AND AIMS: Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood. Our aim was to evaluate serum IL-31 as a putative biomarker of pruritus in clinical trials of ... Full text Link to item Cite

Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B.

Journal Article Hepatology · September 2022 BACKGROUND AND AIMS: Treatment of immune-tolerant (IT) children and adults with combined peginterferon alfa-2a and entecavir results in a decline in serum HBeAg and HBsAg concentrations but rarely results in loss of HBeAg or sustained off-treatment respons ... Full text Link to item Cite

Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis

Journal Article eClinicalMedicine · August 1, 2022 Background: Non-alcoholic steatohepatitis (NASH) is the second-leading indication for liver transplantation (LT) worldwide and is projected to become the leading indication. Our study aimed to determine clinical variables that predict post-LT survival in N ... Full text Cite

An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution.

Journal Article Liver Int · July 2022 BACKGROUND AND AIMS: Liver fibrosis results from a prolonged wound healing response to continued injury with excessive production of extracellular proteins. In patients with chronic liver disease, the monitoring of liver fibrosis dynamics is of high intere ... Full text Link to item Cite

Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank.

Journal Article Hepatol Int · April 2022 BACKGROUND: Lean NAFLD may differ from NAFLD found in overweight or obese patients. We used the UK biobank to conduct a cross-sectional study that examined features that distinguish lean NAFLD from overweight or obese NAFLD. METHODS: MRI-PDFF data were use ... Full text Link to item Cite

Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study.

Journal Article Lancet Digit Health · March 2022 BACKGROUND: Cirrhosis is the result of advanced scarring (or fibrosis) of the liver, and is often diagnosed once decompensation with associated complications has occurred. Current non-invasive tests to detect advanced liver fibrosis have limited performanc ... Full text Link to item Cite

Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.

Journal Article J Am Heart Assoc · January 4, 2022 Background Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. Cardiovascular disease (CVD) is the leading cause of mortality among patients with NAFLD. The aim of our study was to develop a machine learning algorithm in ... Full text Link to item Cite

Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)

Journal Article Canadian Liver Journal · January 1, 2022 Non-alcoholic fatty liver disease (NAFLD) affects approximately 8 million Canadians. NAFLD refers to a disease spectrum ranging from bland steatosis to non-alcoholic steatohepatitis (NASH). Nearly 25% of patients with NAFLD develop NASH, which can progress ... Full text Cite

The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single-Center Analysis.

Journal Article Liver Transpl · December 2021 Organ allocation in liver transplantation (LT) remains imperfect. Periodic center reviews ensure programs transparently evaluate the impact of practice on access to transplantation, reflecting, in particular, patient (primary disease, social determinants) ... Full text Link to item Cite

Incidence of spontaneous bacterial peritonitis among asymptomatic cirrhosis patients undergoing outpatient paracentesis: a systematic review and meta-analysis.

Journal Article Eur J Gastroenterol Hepatol · December 1, 2021 INTRODUCTION: Spontaneous bacterial peritonitis (SBP) is a common complication of decompensated cirrhosis with high morbidity and mortality rate. There is a paucity of evidence regarding the incidence of SBP in asymptomatic liver cirrhosis patients undergo ... Full text Link to item Cite

A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.

Journal Article Dig Dis Sci · November 2021 BACKGROUND AND AIMS: Advanced F3-4 fibrosis predicts liver-related mortality in nonalcoholic fatty liver disease (NAFLD). Noninvasive tests, designed to rule in/out advanced fibrosis, are limited by indeterminates, necessitating biopsy. We aimed to determi ... Full text Link to item Cite

Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study.

Journal Article J Viral Hepat · November 2021 Hepatitis B e antigen (HBeAg) is a soluble viral protein in plasma of patients with hepatitis B virus infection. HBeAg loss is an important first stage of viral antigen clearance. We determined the rate and predictors of HBeAg loss in a North American coho ... Full text Link to item Cite

Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B

Journal Article JHEP Reports · October 1, 2021 Background & Aims: A recent consensus document has defined metabolic dysfunction-associated fatty liver disease (MAFLD) as hepatic steatosis together with overweight, diabetes, and/or a combination of other metabolic risk factors. The clinical relevance of ... Full text Cite

Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease.

Journal Article Sci Rep · September 29, 2021 Reliable and available non-invasive methods for hepatic fibrosis assessment are important in chronic liver disease (CLD). Our aim was to compare stepwise algorithms combining standard ultrasound with serum markers and transient elastography (TE) for detect ... Full text Link to item Cite

Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.

Journal Article J Diabetes Complications · September 2021 Liver disease has emerged as a significant cause of death in people with type 2 diabetes (T2D). Due to a common underlying pathogenic mechanism, namely insulin resistance, T2D represents the main risk factor for nonalcoholic fatty liver disease (NAFLD), ch ... Full text Link to item Cite

Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America.

Journal Article J Viral Hepat · July 2021 BACKGROUND: In chronic hepatitis B (CHB) viral infection, e antigen positivity (HBeAg+) is associated with high levels of viral replication and infectivity. Furthermore, HBeAg-positive CHB is associated with a liver disease spectrum ranging from none to se ... Full text Link to item Cite

Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.

Journal Article Hepatology · June 2021 BACKGROUND AND AIMS: Outcomes of persons with chronic hepatitis B virus (HBV) infection in the era of antiviral therapy (AVT) are not well characterized. We determined the incidence and factors associated with clinical outcomes in a multiethnic, North Amer ... Full text Link to item Cite

A canadian survey on knowledge of non-alcoholic fatty liver disease among physicians

Journal Article Canadian Liver Journal · March 1, 2021 BACKGROUND: In Canada, non-alcoholic fatty liver disease (NAFLD) is the most frequently occurring liver disease, affecting one in four Canadians. NAFLD can in turn evolve into non-alcoholic steatohepatitis (NASH) and cirrhosis. No study in Canada has inves ... Full text Cite

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.

Journal Article Hepatology · February 2021 BACKGROUND AND AIMS: Advanced fibrosis attributable to NASH is a leading cause of end-stage liver disease. APPROACH AND RESULTS: In this phase 2b trial, 392 patients with bridging fibrosis or compensated cirrhosis (F3-F4) were randomized to receive placebo ... Full text Link to item Cite

NASH in HIV.

Journal Article Curr HIV/AIDS Rep · December 2020 PURPOSE OF REVIEW: Aging-related comorbidities, including liver disease, represent the main drivers of morbidity and mortality in people with HIV (PWH). Nonalcoholic fatty liver disease (NAFLD) seems a frequent comorbidity in aging PWH nowadays. NAFLD resu ... Full text Link to item Cite

Reply.

Journal Article Hepatology · December 2020 Full text Link to item Cite

Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection.

Journal Article J Infect Dis · November 13, 2020 BACKGROUND: Advanced liver disease due to hepatitis C virus (HCV) is a leading cause of human immunodeficiency virus (HIV)-related morbidity and mortality. There remains a need to develop noninvasive predictors of clinical outcomes in persons with HIV/HCV ... Full text Link to item Cite

Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.

Journal Article Int J Mol Sci · September 15, 2020 Hepatocellular carcinoma (HCC) is a leading cause of cancer-related morbidity and mortality worldwide. Most patients are diagnosed with advanced disease, limiting their options for treatment. While current treatments are adequate for lower staged disease, ... Full text Link to item Cite

Hepatic Stellate Cells and Hepatocarcinogenesis

Journal Article Frontiers in Cell and Developmental Biology · August 5, 2020 Hepatic stellate cells (HSCs) are a significant component of the hepatocellular carcinoma (HCC) tumor microenvironment (TME). Activated HSCs transform into myofibroblast-like cells to promote fibrosis in response to liver injury or chronic inflammation, le ... Full text Cite

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.

Journal Article Hepatology · July 2020 BACKGROUND AND AIMS: We evaluated the safety and efficacy of cilofexor (formerly GS-9674), a small-molecule nonsteroidal agonist of farnesoid X receptor, in patients with nonalcoholic steatohepatitis (NASH). APPROACH AND RESULTS: In this double-blind, plac ... Full text Link to item Cite

Limitations of non-invasive tests for assessment of liver fibrosis

Journal Article JHEP Reports · April 1, 2020 The diagnostic assessment of liver injury is an important step in the management of patients with chronic liver disease (CLD). Although liver biopsy is the reference standard for the assessment of necroinflammation and fibrosis, the inherent limitations of ... Full text Cite

Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B.

Journal Article Hepatology · February 2020 BACKGROUND AND AIMS: Chronic hepatitis B (CHB) and nonalcoholic fatty liver disease are increasingly observed together in clinical practice, and development of nonalcoholic steatohepatitis (NASH) represents another leading cause of liver-related morbidity ... Full text Link to item Cite

Reply.

Journal Article Hepatology · February 2020 Full text Link to item Cite

Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox.

Conference Liver Transpl · January 2020 Morbid obesity is considered a relative contraindication for liver transplantation (LT). We investigated if body mass index (BMI; lean versus obese) is a risk factor for post-LT graft and overall survival in nonalcoholic steatohepatitis (NASH) and non-NASH ... Full text Link to item Cite

Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice?

Journal Article Aliment Pharmacol Ther · January 2020 Full text Link to item Cite

Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study.

Journal Article CMAJ Open · 2020 BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) account for a growing proportion of liver disease cases, and there is a need to better understand future disease burden. We used a modelling framework to forecast ... Full text Link to item Cite

The z-profile study: A multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in canadian adult patients with chronic hepatitis c

Journal Article Canadian Liver Journal · January 1, 2020 BACKGROUND: Canada was the first country to approve elbasvir/grazoprevir (EBR/GZR) for the treatment of chronic HCV infection for genotypes 1 and 4 with or without ribavirin and genotype 3 with sofosbuvir, with no recommendation for baseline resistance tes ... Full text Cite

Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Journal Article Clin Gastroenterol Hepatol · November 2019 BACKGROUND & AIMS: The incidence and outcomes of alanine aminotransferase (ALT) flares during the natural history of chronic HBV infection has not been determined in a large, racially heterogeneous group of patients in North America. METHODS: We collected ... Full text Link to item Cite

Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B.

Journal Article J Viral Hepat · July 2019 Hepatitis B e antigen (HBeAg) is an important serological marker of hepatitis B virus (HBV) infection and is associated with higher levels of viraemia, increased risk of infectivity to others and increased risk of hepatocellular carcinoma. We analysed HBeA ... Full text Link to item Cite

Reply.

Journal Article Liver Transpl · June 2019 Full text Link to item Cite

Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations.

Journal Article Proteomics Clin Appl · May 2019 PURPOSE: In the interferon era of hepatitis C virus (HCV) therapies, genotype/subtype, cirrhosis, prior treatment failure, sex, and race predicted relapse. Our objective is to validate a targeted proteomics platform of 17 peptides to predict sustained viro ... Full text Link to item Cite

Living in Food Deserts and Adverse Cardiovascular Outcomes in Patients With Cardiovascular Disease.

Journal Article J Am Heart Assoc · February 19, 2019 Background Food deserts ( FDs ), defined as low-income communities with limited access to healthy food, are a growing public health concern. We evaluated the impact of living in FDs on incident cardiovascular events. Methods and Results We recruited 4944 s ... Full text Link to item Cite

Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.

Journal Article Am J Physiol Gastrointest Liver Physiol · January 1, 2019 There is a need for noninvasive biomarkers that can identify patients with progressive liver fibrosis and monitor response to antifibrotic therapy. An equally important need is identification of patients with spontaneous fibrosis regression, since they may ... Full text Link to item Cite

Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.

Journal Article Liver Transpl · January 2019 Nonalcoholic fatty liver disease (NAFLD) can occur de novo in patients undergoing liver transplantation (LT) for indications other than NAFLD, and it has been increasingly recognized as a complication in the post-LT setting. This study aims to better chara ... Full text Link to item Cite

Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension.

Journal Article Can J Gastroenterol Hepatol · 2019 Non-cirrhotic portal hypertension (NCPH) comprises a heterogeneous group of liver disorders causing portal hypertension without cirrhosis and carries a high risk of variceal bleeding. Recent guidelines, based largely on patients with viral cirrhosis, sugge ... Full text Link to item Cite

Viral hepatitis

Chapter · January 1, 2019 Hepatitis B (HBV) and C (HCV) chronically infect > 300 million people globally and represent leading virologic causes of end-stage liver disease and hepatocellular carcinoma. Hepatitis A and E are typically characterized by acute hepatitis and mostly follo ... Full text Cite

Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure.

Journal Article Cell Mol Gastroenterol Hepatol · 2019 Full text Link to item Cite

Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Journal Article Hepatol Commun · November 2018 The severity of hepatic fibrosis is the primary predictor of liver-related morbidity and mortality in patients with nonalcoholic fatty liver disease (NAFLD). Unfortunately, noninvasive serum biomarkers for NAFLD-associated fibrosis are limited. We analyzed ... Full text Link to item Cite

Temporal Changes in Cardiovascular Remodeling Associated with Football Participation.

Journal Article Med Sci Sports Exerc · September 2018 PURPOSE: American-style football (ASF) participation rates in the United States are highest among high school (HS) athletes. This study sought to compare the cardiovascular response to HS versus collegiate ASF participation. METHODS: The ASF participants ( ... Full text Link to item Cite

Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma.

Journal Article Expert Rev Mol Diagn · August 2018 Chronic liver disease due to viral hepatitis continues to be a major global health concern. Timely diagnosis and treatment will prevent cirrhosis, risk of hepatocellular carcinoma (HCC), and requirement for liver transplantation. Numerous serum biomarkers ... Full text Link to item Cite

Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.

Journal Article Clin Infect Dis · May 17, 2018 BACKGROUND: While the necessity of treatment of hepatitis C virus (HCV)-infected patients with advanced liver disease is widely accepted, the benefit of treating patients without significant liver disease is less well established. Our aim was to assess the ... Full text Link to item Cite

High-Sensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Long-Term Outcomes.

Journal Article J Am Heart Assoc · February 21, 2018 BACKGROUND: The associations between high-sensitivity troponin I (hsTnI) levels and coronary artery disease (CAD) severity and progression remain unclear. We investigated whether there is an association between hsTnI and angiographic severity and progressi ... Full text Link to item Cite

Marital Status and Outcomes in Patients With Cardiovascular Disease.

Journal Article J Am Heart Assoc · December 20, 2017 BACKGROUND: Being unmarried is associated with decreased survival in the general population. Whether married, divorced, separated, widowed, or never-married status affects outcomes in patients with cardiovascular disease has not been well characterized. ME ... Full text Link to item Cite

Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment.

Journal Article J Viral Hepat · November 2017 Antiviral drug resistance hepatitis B virus (HBV) variants (HBV-DR) occur spontaneously in chronic hepatitis B (CHB) patients and after exposure to nucleos(t)ide analogues (NUCs). We determined the prevalence of HBV-DR variants among participants of the He ... Full text Link to item Cite

Sleep-Disordered Breathing and Cardiovascular Correlates in College Football Players.

Journal Article Am J Cardiol · October 15, 2017 This study sought to determine the cardiovascular physiologic correlates of sleep-disordered breathing (SDB) in American-style football (ASF) participants using echocardiography, vascular applanation tonometry, and peripheral arterial tonometry. Forty coll ... Full text Link to item Cite

Association Between Living in Food Deserts and Cardiovascular Risk.

Journal Article Circ Cardiovasc Qual Outcomes · September 2017 BACKGROUND: Food deserts (FD), neighborhoods defined as low-income areas with low access to healthy food, are a public health concern. We evaluated the impact of living in FD on cardiovascular risk factors and subclinical cardiovascular disease (CVD) with ... Full text Link to item Cite

Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Journal Article Atherosclerosis · September 2017 BACKGROUND AND AIMS: Circulating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse ... Full text Link to item Cite

Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.

Journal Article Clin Gastroenterol Hepatol · July 2017 BACKGROUND & AIMS: Despite complete suppression of viral DNA with antiviral agents, in some patients with chronic hepatitis B (CHB), serum levels of alanine aminotransferase (ALT) do not normalize. We investigated factors associated with persistent increas ... Full text Link to item Cite

An improved LC-MS/MS method for the quantification of alverine and para hydroxy alverine in human plasma for a bioequivalence study^☆

Journal Article Journal of Pharmaceutical Analysis · April 1, 2017 A highly sensitive and selective high performance liquid chromatography-tandem mass spectrometry method was developed and validated for the quantification of alverine (ALV) and its active metabolite, para hydroxy alverine (PHA), in human plasma. For sample ... Full text Cite

Determination of hepatitis B phenotype using biochemical and serological markers.

Journal Article J Viral Hepat · April 2017 The aim of this study was to assess the validity of categorization of chronic hepatitis B viral infection into stages or phases based upon measures of disease activity and viral load, assuming these phenotypes will be useful for prognostication and determi ... Full text Link to item Cite

Viral Hepatitis

Chapter · March 23, 2017 Viral hepatitis is a highly prevalent cause of human morbidity and mortality. Consequences of chronic infection include liver failure and liver cancer. Genomic medicine has seen significant advances in the management and prognosis of viral hepatitis infect ... Full text Cite

Depression and chest pain in patients with coronary artery disease.

Journal Article Int J Cardiol · March 1, 2017 BACKGROUND: Depression is common in patients with coronary artery disease (CAD) and is associated with more frequent chest pain. It is however unclear whether this is due to differences in underlying CAD severity. We sought to determine [1] whether depress ... Full text Link to item Cite

Pancreatic Safety of Sitagliptin in the TECOS Study.

Journal Article Diabetes Care · February 2017 OBJECTIVE: We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i). RESEARCH DESIGN AND METHODS: In th ... Full text Link to item Cite

Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Journal Article Drugs · February 2017 Hepatitis C virus (HCV) represents a significant global disease burden, with an estimated 130-150 million people worldwide living with chronic HCV infection. Within the six major clinical HCV genotypes, genotype 3 represents 22-30% of all infection and is ... Full text Link to item Cite

Simultaneous analysis of allopurinol and oxypurinol using a validated liquid chromatography–tandem mass spectrometry method in human plasma

Journal Article Journal of Pharmaceutical Analysis · February 1, 2017 The present study describes a simple, reliable and reproducible liquid chromatography–tandem mass spectrometry method (LC–MS/MS) for the simultaneous determination of allopurinol and its active metabolite, oxypurinol in human plasma for a pharmacokinetic/b ... Full text Cite

Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis.

Journal Article PLoS One · 2017 Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world, and encompasses a spectrum from simple steatosis to steatohepatitis (NASH). There is currently no approved pharmacologic therapy against NASH, partly d ... Full text Link to item Cite

Advances in salt point management practices: Mitigating overhead corrosion with big data

Conference Fuels and Petrochemicals Division 2017 - Core Programming Area at the AIChE Annual Meeting · January 1, 2017 In the world of overhead corrosion, it has long been recognized colloquially that ninety percent of metal loss occurs during ten percent of the time in operation. In many types of fractionating tower overheads, a confluence of fluctuating dynamical factors ... Cite

Advances in salt point management practices: Mitigating overhead corrosion with big data

Conference Separations Division 2017 - Core Programming Area at the 2017 AIChE Annual Meeting · January 1, 2017 In the world of overhead corrosion, it has long been recognized colloquially that ninety percent of metal loss occurs during ten percent of the time in operation. In many types of fractionating tower overheads, a confluence of fluctuating dynamical factors ... Cite

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.

Journal Article Am J Physiol Gastrointest Liver Physiol · December 1, 2016 There are no approved treatments for liver fibrosis. To aid development of antifibrotic therapies, noninvasive biomarkers that can identify patients with progressive fibrosis and that permit monitoring of the response to antifibrotic therapy are much neede ... Full text Link to item Cite

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.

Journal Article Clin Infect Dis · October 15, 2016 BACKGROUND: Until recently, the approved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks. The impact of RBV-free pan-genotypic regimen with SOF and velpata ... Full text Link to item Cite

Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

Journal Article Curr HIV/AIDS Rep · October 2016 Patients with HIV have a proclivity to develop liver fibrosis, especially when associated with other conditions such as HCV, HBV, and NAFLD. Identifying HIV-infected patients with significant fibrosis or cirrhosis plays an important role in clinical and th ... Full text Link to item Cite

Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.

Journal Article Hepatology · September 2016 Full text Link to item Cite

Liquid chromatography–tandem mass spectrometry method for simultaneous determination of albendazole and albendazole sulfoxide in human plasma for bioequivalence studies

Journal Article Journal of Pharmaceutical Analysis · August 1, 2016 An improved high performance liquid chromatography–tandem mass spectrometry (LC–MS/MS) method has been developed for sensitive and rapid determination of albendazole (ABZ) and its active metabolite, albendazole sulfoxide (ABZSO), in the positive ionization ... Full text Cite

Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.

Journal Article Gastroenterology · June 2016 Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of histopathologic features, ranging from isolated hepatic steatosis, to steatohepatitis with evidence of hepatocellular injury and fibrosis, to cirrhosis. The diagnosis and determination of NAF ... Full text Link to item Cite

Application of an LC-MS/MS method for reliable determination of amodiaquine, N-desethylamodiaquine, artesunate and dihydroartemisinin in human plasma for a bioequivalence study in healthy Indian subjects.

Journal Article J Pharm Biomed Anal · May 30, 2016 A sensitive and high throughput bioanalytical method has been developed for reliable determination of amodiaquine (AQ), N-desethylamodiaquine (DEAQ), artesunate (AS) and dihydroartemisinin (DHA) in human plasma by LC-MS/MS. The method employs a solid phase ... Full text Link to item Cite

Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.

Journal Article Aliment Pharmacol Ther · February 2016 BACKGROUND: Assessment of fibrosis progression in chronic liver disease relies upon non-invasive tools and changes in semi-quantitative histopathology scores that may not be reliable. AIM: To assess the diagnostic performance of the FibroSURE (FS) index an ... Full text Link to item Cite

Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.

Journal Article J Hepatol · January 2016 BACKGROUND & AIMS: Hepatitis C virus (HCV) modulates host lipid metabolism for its replication and lifecycle. Our aims were to assess changes in the serum lipid and distal (post-squalene) cholesterol biosynthesis metabolite profile of HCV genotypes (GT) 2 ... Full text Link to item Cite

Homologous Recombination and Translesion DNA Synthesis Play Critical Roles on Tolerating DNA Damage Caused by Trace Levels of Hexavalent Chromium.

Journal Article PLoS One · 2016 Contamination of potentially carcinogenic hexavalent chromium (Cr(VI)) in the drinking water is a major public health concern worldwide. However, little information is available regarding the biological effects of a nanomoler amount of Cr(VI). Here, we inv ... Full text Link to item Cite

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Journal Article N Engl J Med · December 31, 2015 BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C viru ... Full text Link to item Cite

Diabetes and prediabetes in patients with hepatitis B residing in North America.

Journal Article Hepatology · November 2015 UNLABELLED: Diabetes is associated with liver disease progression and increased hepatocellular carcinoma risk, but factors associated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North America are unknown. We aimed to determi ... Full text Link to item Cite

MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection.

Journal Article J Med Virol · October 2015 miR-122 is the predominant liver miRNA that regulates hepatic lipid metabolism and inflammation. Hepatitis C virus (HCV) modulates host intracellular lipid metabolism. HCV stability and propagation also depend on an interaction between virus and miR-122. O ... Full text Link to item Cite

Histologic and noninvasive estimates of liver fibrosis.

Journal Article Clin Liver Dis (Hoboken) · July 2015 Full text Link to item Cite

Diagnosis of liver fibrosis: present and future.

Journal Article Semin Liver Dis · May 2015 The diagnostic assessment of liver fibrosis, a major determinant of disease severity, is an important step in the management of patients with chronic liver diseases. Liver biopsy is still considered the gold standard for the assessment of necroinflammation ... Full text Link to item Cite

Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study.

Journal Article Clin Gastroenterol Hepatol · April 2015 BACKGROUND & AIMS: Liver biopsy is invasive and associated with complications, sampling errors, and observer variability. Vibration-controlled transient elastography (VCTE) with FibroScan can be used to immediately assess liver stiffness. We aimed to defin ... Full text Link to item Cite

Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals.

Journal Article Open Forum Infect Dis · April 2015 We evaluated the impact of antiretroviral-induced dyslipidemia on hepatitis C virus (HCV) biogenesis in human immunodeficiency virus (HIV)/HCV coinfected patients. This study used serum samples from antiretroviral-naive HIV/HCV patients initiating their fi ... Full text Open Access Link to item Cite

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

Journal Article Hepatology · March 2015 UNLABELLED: Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to ... Full text Link to item Cite

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

Journal Article Liver Int · February 2015 BACKGROUND & AIMS: Fibrogenesis results in release of certain extracellular matrix protein fragments into the circulation. We evaluated the diagnostic and prognostic performance of two novel serological markers, the precisely cleaved N-terminal propeptide ... Full text Link to item Cite

Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype.

Journal Article Clin Gastroenterol Hepatol · January 2015 BACKGROUND & AIMS: Chronic hepatitis B virus (HBV) infection is an important cause of cirrhosis and hepatocellular carcinoma worldwide; populations that migrate to the United States and Canada might be affected disproportionately. The Hepatitis B Research ... Full text Link to item Cite

Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C.

Journal Article Clin Gastroenterol Hepatol · December 2014 BACKGROUND & AIMS: Noninvasive tests cannot differentiate between adjacent stages of fibrosis, which limits assessment of disease progression and regression during therapy. We investigated whether levels of cytokines and extracellular matrix proteins in se ... Full text Link to item Cite

Fibroscan.

Journal Article Clin Liver Dis (Hoboken) · November 2014 Full text Link to item Cite

Trends in hepatitis C treatment uptake in the United States.

Journal Article Hepatology · August 2014 Full text Link to item Cite

Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication.

Journal Article Clin Sci (Lond) · June 2014 OPN (osteopontin)) is a Hh (Hedgehog)-regulated cytokine that is up-regulated during chronic liver injury and directly promotes fibrosis. We have reported that Hh signalling enhances viral permissiveness and replication in HCV (hepatitis C virus)-infected ... Full text Link to item Cite

Current status of fibrosis markers.

Journal Article Curr Opin Gastroenterol · May 2014 PURPOSE OF REVIEW: Improved understanding of the pathophysiology of fibrosis and recent technological advances have resulted in the development of several serum biomarkers and imaging tools as noninvasive alternatives to biopsy. Most of these markers have ... Full text Link to item Cite

A rationalized approach to the treatment of patients infected with hepatitis B.

Journal Article Mol Diagn Ther · April 2014 It is estimated that there are 350-400 million individuals with chronic hepatitis B virus infection (HBV) worldwide. The natural course of HBV infection is variable with a number of individuals developing no or only mild disease, while others will die from ... Full text Link to item Cite

Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Journal Article Mol Diagn Ther · February 2014 Hepatitis C virus—a major global cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma—affects millions of people worldwide. Pegylated interferon (Peg-IFN) and ribavirin (RBV) had been the standard treatment for a decade until availability of ... Full text Link to item Cite

Fulminant herpes simplex viral hepatitis: ultrasound and CT imaging appearance and a review of the imaging literature.

Journal Article Clin Imaging · 2014 We report the case of a previously healthy 21-year-old woman who presented 6 days post-partum in acute fulminant hepatic failure. A liver ultrasound demonstrated normal echogenicity without discrete nodules while an enhanced computed tomography (CT) demons ... Full text Link to item Cite

The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease.

Journal Article Med Devices (Auckl) · 2014 An important aspect of managing chronic liver disease is assessing for evidence of fibrosis. Historically, this has been accomplished using liver biopsy, which is an invasive procedure associated with risk for complications and significant sampling and obs ... Full text Open Access Link to item Cite

Therapy of acute and fulminant hepatitis B.

Journal Article Intervirology · 2014 Although new hepatitis B virus (HBV) infections are decreasing due to improving vaccination coverage, patients without vaccination coverage can still suffer from manifestation of acute hepatitis B with jaundice and (although rarely) liver failure. No treat ... Full text Link to item Cite

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

Journal Article J Viral Hepat · December 2013 Anaemia frequently complicates peginterferon/ribavirin therapy for chronic hepatitis C infection. Better prediction of anaemia, ribavirin dose reduction or erythropoietin (EPO) need, may enhance patient management. Inosine triphosphatase (ITPA) genetic var ... Full text Link to item Cite

Viral Hepatitis

Journal Article · August 29, 2013 Full text Cite

Cirrhosis

Journal Article · August 29, 2013 Full text Cite

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Journal Article N Engl J Med · May 16, 2013 BACKGROUND: Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options. In ph ... Full text Link to item Cite

Treatment of HCV infection by targeting microRNA.

Journal Article N Engl J Med · May 2, 2013 BACKGROUND: The stability and propagation of hepatitis C virus (HCV) is dependent on a functional interaction between the HCV genome and liver-expressed microRNA-122 (miR-122). Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oli ... Full text Link to item Cite

Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection.

Journal Article Hum Genet · December 2012 Hepatitis C virus (HCV) modulates host lipid metabolism as part of its lifecycle and is dependent upon VLDL for co-assembly and secretion. HCV dyslipidemia is associated with steatosis, insulin resistance, IL28B genotype and disease progression. Apolipopro ... Full text Link to item Cite

Cirrhosis

Chapter · November 15, 2012 Full text Cite

Viral Hepatitis

Chapter · November 15, 2012 Full text Cite

New agents for the treatment of hepatitis C virus - Focus on telaprevir

Journal Article Virus Adaptation and Treatment · October 31, 2012 Antiviral therapy for hepatitis C virus (HCV) is rapidly evolving with the advent of direct-acting antiviral agents. Telaprevir is a first-generation linear ketoamide inhibitor of HCV NS3 protease. Approved in 2011 as standard-of-care for the treatment of ... Full text Cite

Erratum: The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis c infection (Digestive Diseases and Sciences (2012) 57 (2479))

Journal Article Digestive Diseases and Sciences · September 1, 2012 Full text Cite

The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.

Journal Article Dig Dis Sci · August 2012 BACKGROUND: Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined. AIM: We sought to validate thes ... Full text Link to item Cite

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Journal Article Hepatology · August 2012 UNLABELLED: Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (P ... Full text Link to item Cite

Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection.

Journal Article Clin Gastroenterol Hepatol · August 2012 BACKGROUND & AIMS: Hepatic elastography (HE) is a noninvasive technique that measures liver stiffness and is used to diagnose hepatic fibrosis. It can help patients who are thought to have early-stage disease avoid a staging liver biopsy, but only when con ... Full text Link to item Cite

Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner.

Journal Article Hepatology · July 2012 UNLABELLED: Hepatitis C virus (HCV) subverts host cholesterol metabolism for key processes in its lifecycle. How this interference results in the frequently observed, genotype-dependent clinical sequelae of hypocholesterolemia, hepatic steatosis, and insul ... Full text Link to item Cite

Metaprotein expression modeling for label-free quantitative proteomics.

Journal Article BMC Bioinformatics · May 4, 2012 BACKGROUND: Label-free quantitative proteomics holds a great deal of promise for the future study of both medicine and biology. However, the data generated is extremely intricate in its correlation structure, and its proper analysis is complex. There are i ... Full text Link to item Cite

Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.

Journal Article J Viral Hepat · May 2012 Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection. IL28B has been linked with LDL-C ... Full text Link to item Cite

Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis.

Journal Article Hepatol Int · April 2012 BACKGROUND: The hepatitis C virus (HCV) is known to disrupt lipid metabolism, making serum lipoprotein levels good candidates to explore as markers of HCV disease progression. Assessment of the major apolipoproteins (Apo) and their relationship to hepatic ... Full text Link to item Cite

Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis.

Journal Article J Viral Hepat · April 2012 Cytokeratin-18 (CK-18) is a major intermediate filament protein in liver cells. The M30 fragment of CK-18 has been identified as a useful marker of apoptosis associated with fibrosis and steatosis in nonalcoholic steatohepatitis (NASH). We sought to assess ... Full text Link to item Cite

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.

Journal Article J Hepatol · February 2012 BACKGROUND & AIMS: Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related ... Full text Link to item Cite

The potential influence of Internet-based social networking on the conduct of clinical research studies.

Journal Article J Empir Res Hum Res Ethics · February 2012 The rapid growth of internet usage has led to an explosion of social networking sites for discussion of health issues. This provides a forum for subjects to communicate with one another during the course of the studies. Previous studies have raised concern ... Full text Link to item Cite

Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.

Journal Article Gut · January 2012 OBJECTIVES: Genotype-specific associations between hepatitis C virus (HCV) and insulin resistance (IR) have been described, but a causal relationship remains unclear. This study investigated the association between a sustained virological response (SVR) an ... Full text Link to item Cite

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.

Journal Article J Hepatol · December 2011 BACKGROUND & AIMS: IL28B polymorphisms have been associated with both treatment induced and spontaneous clearance of hepatitis C virus (HCV). We previously found that LDL cholesterol levels were higher in chronic hepatitis C (CHC) patients with the CC geno ... Full text Link to item Cite

FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

Journal Article World J Gastroenterol · November 7, 2011 AIM: To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. METHODS: Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes ... Full text Link to item Cite

Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?

Journal Article Hepatology · October 2011 Noninvasive biomarkers of liver fibrosis represent an intense area of research with the goals of improving patient care, disease stratification, and aiding the development of future antifibrotic therapies. Despite the rapid progress in recent years, there ... Full text Link to item Cite

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

Journal Article Clin Gastroenterol Hepatol · August 2011 BACKGROUND & AIMS: It is recommended that patients with chronic hepatitis C virus (HCV) genotype 3 infections receive 24 weeks of treatment. A rapid virologic response (RVR; at week 4) predicts a sustained virologic response (SVR), although not all patient ... Full text Link to item Cite

Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients.

Journal Article J Gastroenterol Hepatol · July 2011 BACKGROUND AND AIM: The role of insulin resistance (IR) and hepatic steatosis in fibrogenesis in chronic hepatitis C infection (CHC) has yielded conflicting data and few studies have been performed in Asian-region populations. We retrospectively investigat ... Full text Link to item Cite

High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients.

Journal Article Hepatology · June 2011 UNLABELLED: Chronic hepatitis C (CHC) infection is a leading cause of endstage liver disease. Current standard-of-care (SOC) interferon-based therapy results in sustained virological response (SVR) in only one-half of patients, and is associated with signi ... Full text Link to item Cite

Noninvasive tools to assess liver disease.

Journal Article Curr Opin Gastroenterol · May 2011 PURPOSE OF REVIEW: To improve understanding of recent developments in the noninvasive assessment of fibrosis and their potential clinical application to a range of chronic liver diseases. RECENT FINDINGS: Many noninvasive tests have evolved from their prim ... Full text Link to item Cite

Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.

Journal Article J Viral Hepat · May 2011 HMG CoA reductase inhibition suppresses in vitro HCV replication through depletion of cellular sterol proteins such as geranylgeraniol. Our aims were to prospectively evaluate the changes in serum and lipid fraction HCV RNA with Rosuvastatin in non-respond ... Full text Link to item Cite

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Journal Article Hepatology · February 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepati ... Full text Link to item Cite

Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C.

Journal Article PLoS One · 2011 INTRODUCTION: Polymorphisms near the IL28B gene (e.g. rs12979860) encoding interferon λ3 have recently been associated with both spontaneous clearance and treatment response to pegIFN/RBV in chronic hepatitis C (CHC) patients. The molecular consequences of ... Full text Link to item Cite

Single-dose, Two-way Crossover, Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

Journal Article Clinical Therapeutics · 2011 Background: Mycophenolate mofetil (MMF) is an immunosuppressant indicated for prophylaxis of acute organ transplant rejection. Generic MMF is less costly than the branded product, but European regulatory authorities require bioequivalence studies for the m ... Full text Cite

Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients.

Journal Article Antivir Ther · 2011 BACKGROUND: 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors inhibit HCV replication in vitro. The combination of sertraline and simvastatin has synergistic antiviral activity in vitro, but there are no prior in vivo studies. Our aims were to pr ... Full text Link to item Cite

Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.

Journal Article Hepatology · December 2010 Full text Link to item Cite

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

Journal Article Hepatology · December 2010 UNLABELLED: Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC) who were treated with peginterferon-α and ribavirin. We ... Full text Link to item Cite

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.

Journal Article Gastroenterology · November 2010 BACKGROUND & AIMS: A single nucleotide polymorphism (SNP) upstream of the IL28B gene has been associated with response of patients with chronic hepatitis C to therapy with pegylated interferon and ribavirin and also with spontaneous clearance of acute hepa ... Full text Link to item Cite

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Journal Article Gastroenterology · October 2010 BACKGROUND & AIMS: In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic ane ... Full text Link to item Cite

Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue.

Journal Article Res Nurs Health · October 2010 We identified trajectories of illness uncertainty in chronic hepatitis C patients and examined their association with fatigue levels during 12 months of disease monitoring without treatment (watchful waiting). Sixty-two men and 63 women completed uncertain ... Full text Link to item Cite

Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.

Journal Article J Antimicrob Chemother · October 2010 Chronic hepatitis C virus (HCV) infection is a global health problem, but the current therapy is effective in <50% of patients infected with genotype 1. With advances in cell culture systems over the past decade, the development of directly acting antivira ... Full text Link to item Cite

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

Journal Article Gastroenterology · October 2010 BACKGROUND & AIMS: A phase 3 active-controlled study was conducted to assess the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of recombinant human albumin and interferon alfa-2b, in patients with chron ... Full text Link to item Cite

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.

Journal Article Gastroenterology · September 2010 BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)-28B gene on chromosome 19 have been associated with peginterferon-alfa-induced clearance of genotype 1 hepatitis C virus (HCV); there are no data for patients with genotype 2 or 3 HCV. ... Full text Link to item Cite

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

Journal Article Hepatology · September 2010 UNLABELLED: Elevated low-density lipoprotein (LDL) levels and statin use have been associated with higher sustained virological response (SVR) rates in patients receiving chronic hepatitis C therapy. However, these relationships have not been well characte ... Full text Link to item Cite

The use of complementary and alternative medicine by patients with chronic hepatitis C.

Journal Article Complement Ther Clin Pract · August 2010 BACKGROUND: The use of complementary and alternative medicine (CAM) is expanding globally. However, prevalence of its use by patients with chronic hepatitis C (CHC) remains unclear. METHODS: An exploratory, descriptive study was conducted using a questionn ... Full text Link to item Cite

Hepatitis C

Journal Article · July 22, 2010 Full text Cite

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Journal Article Gastroenterology · July 2010 BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatmen ... Full text Link to item Cite

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.

Journal Article Gastroenterology · June 2010 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infections are treated with pegylated interferon and ribavirin (PEG-IFN/RBV), which is effective in less than 50% of those infected with HCV genotype 1. Genome-wide association studies have l ... Full text Link to item Cite

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

Journal Article Hepatology · June 2010 UNLABELLED: Recently, genetic polymorphisms occurring in the interferon (IFN)-lambda gene region were associated with response to IFN-based treatment of hepatitis C infection. Both infection with the hepatitis C virus and IFN therapy are associated with de ... Full text Link to item Cite

Noninvasive tools to assess liver disease.

Journal Article Curr Opin Gastroenterol · May 2010 PURPOSE OF REVIEW: Improved understanding of the pathophysiology of fibrosis and recent technological advances have resulted in the development of several serum biomarkers and imaging tools as noninvasive alternatives to biopsy. This review highlights some ... Full text Link to item Cite

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

Journal Article Gastroenterology · April 2010 BACKGROUND & AIMS: Farglitazar (GI262570), an insulin-sensitizing agent, selectively binds and activates peroxisome proliferator-activated receptor gamma (PPARgamma) and inhibits stellate cell activation. We evaluated its antifibrotic effect in patients wi ... Full text Link to item Cite

Antifibrotic therapies: will we ever get there?

Journal Article Curr Gastroenterol Rep · February 2010 Progressive hepatic fibrosis is the final common pathway for most chronic liver injuries, leading to cirrhosis with risk of liver failure and hepatocellular carcinoma. It is now recognized that fibrosis is a dynamic process, and may be reversible prior to ... Full text Link to item Cite

State of the art treatment of hepatitis C

Chapter · January 1, 2010 Over the last decade, chronic hepatitis C (HCV) infection has seen a dramatic change in the success of treatment with the evolution of standard-of-care. While 24 week standard interferon-alpha monotherapy led to sustained viral response rates in the range ... Cite

Diagnosis, Management and Disease Mechanisms of Hepatitis in the Era of Genomic Medicine

Journal Article · December 1, 2009 Full text Cite

Cirrhosis in the era of genomic medicine

Journal Article · December 1, 2009 Full text Cite

Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.

Journal Article Liver Int · October 2009 BACKGROUND: Albinterferon-alpha-2b (albIFN) is a long-acting fusion polypeptide composed of albumin and IFN-alpha-2b. In a phase 2 study of albIFN 1500 mug q2wk or q4wk in patients with genotype 2/3 chronic hepatitis C, albIFN demonstrated sustained virolo ... Full text Link to item Cite

Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response?

Journal Article Hepatology · October 2009 Full text Link to item Cite

Antisense inhibitors, ribozymes, and siRNAs.

Journal Article Clin Liver Dis · August 2009 The current standard of care for the treatment of hepatitis C virus infection, pegylated interferon-alpha and ribavirin, is costly, associated with significant side effects, and effective in only 50% of patients. There is therefore a need for the developme ... Full text Link to item Cite

An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

Journal Article J Viral Hepat · March 2009 Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral therapy in chronic hepatitis C (CHC). This study compared two commercially available serum marker ... Full text Link to item Cite

Life threatening liver disease during treatment with monoclonal antibodies.

Journal Article BMJ · February 18, 2009 Full text Link to item Cite

Hepatitis B virus viral load and treatment decision.

Journal Article Hepatology · February 2009 Full text Link to item Cite

Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.

Journal Article Curr Gastroenterol Rep · February 2009 Advanced liver disease and interferon-based treatment are both associated with varying degrees of cytopenia in patients with chronic hepatitis C. Growth factors to increase hemoglobin and neutrophils are commonly used in clinical practice, despite the abse ... Full text Link to item Cite

Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges.

Journal Article J Hepatol · January 2009 Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of genotype 1-infected patients. Antiviral agents specifically targeting either the HCV protease or polymerase, or other targets, are now in clinical development. I ... Full text Link to item Cite

Noninvasive assessment of liver fibrosis in chronic hepatitis C infection

Journal Article Current Hepatitis Reports · December 1, 2008 Hepatic fibrogenesis is a dynamic process that reflects a balance between matrix synthesis and degradation. An accurate determination of hepatic fibrosis is important in determining prognosis, requirement for therapy, and disease progression in chronic hep ... Full text Cite

Cirrhosis in the Era of Genomic Medicine

Chapter · November 11, 2008 Full text Cite

Diagnosis, Management and Disease Mechanisms of Hepatitis in the Era of Genomic Medicine

Chapter · November 11, 2008 Full text Cite

Factors influencing the participation of gastroenterologists and hepatologists in clinical research.

Journal Article BMC Health Serv Res · October 8, 2008 BACKGROUND: Although clinical research is integral to the advancement of medical knowledge, physicians face a variety of obstacles to their participation as investigators in clinical trials. We examined factors that influence the participation of gastroent ... Full text Link to item Cite

Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia.

Journal Article J Clin Gastroenterol · August 2008 GOALS: We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia. BACKGROUND: Gastroesophageal variceal ... Full text Link to item Cite

Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.

Journal Article J Viral Hepat · August 2008 Ribavirin has a minor and transient effect on hepatitis C virus (HCV) replication and has been suggested to select a novel mutation, F415Y, in the RNA-dependent RNA polymerase of subtype 1a viruses. Twenty-nine patients with chronic hepatitis C (subtyped b ... Full text Link to item Cite

GBV-C in HIV-HCV coinfection, low liver-related mortality but high overall mortality.

Journal Article Gastroenterology · June 2008 Full text Link to item Cite

Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.

Journal Article Clin Gastroenterol Hepatol · June 2008 BACKGROUND & AIMS: A phase 2, randomized, multicenter, open-label study evaluated the safety and efficacy of albinterferon alfa-2b in interferon-alpha treatment-naïve patients with genotype 2/3, chronic hepatitis C virus infection. METHODS: Forty-three pat ... Full text Link to item Cite

Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.

Journal Article Aliment Pharmacol Ther · March 1, 2008 BACKGROUND: Treatment options are limited for patients with hepatitis C virus who do not experience sustained viral eradication with pegylated interferon and ribavirin therapy. AIM: To compare, in an open-label, randomized study, long-term continuous inter ... Full text Link to item Cite

Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C.

Journal Article Clin Gastroenterol Hepatol · February 2008 BACKGROUND & AIMS: Accurate disease staging in chronic hepatitis C (CHC) infection helps guide treatment and may provide prognostic information. Liver biopsies are invasive, costly, and associated with morbidity. We hypothesized that a noninvasive test of ... Full text Link to item Cite

Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation.

Journal Article J Infect Dis · January 15, 2008 BACKGROUND: Steatosis is a common histological finding and a poor prognostic indicator in patients with hepatitis C virus (HCV) infection. In HCV genotype 3-infected patients, the etiology of steatosis appears to be closely correlated with unknown viral fa ... Full text Link to item Cite

Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection.

Journal Article J Transl Med · July 11, 2007 BACKGROUND: Despite its widespread use to assess fibrosis, liver biopsy has several important drawbacks, including that is it semi-quantitative, invasive, and limited by sampling and observer variability. Non-invasive serum biomarkers may more accurately r ... Full text Link to item Cite

Fibrosis markers in hepatitis C

Journal Article Current Hepatitis Reports · August 1, 2006 Significant morbidity and mortality due to chronic hepatitis C infection have led to efforts to identify patients at risk of progressive disease. Current clinical practice relies on liver biopsy as the gold standard for assessing the severity of chronic he ... Full text Cite

Is compliance with antiviral therapy for chronic hepatitis C lower in intravenous drug users?

Journal Article Nat Clin Pract Gastroenterol Hepatol · July 2006 Full text Link to item Cite

Relationship of smoking and fibrosis in patients with chronic hepatitis C.

Journal Article Clin Gastroenterol Hepatol · June 2006 BACKGROUND & AIMS: Preliminary studies have suggested that in patients with chronic hepatitis C (CHC), cigarette smoking increases the risk for developing liver fibrosis. Hypoxia caused by smoking may induce expression of the cytokines' vascular endothelia ... Full text Link to item Cite

Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo.

Journal Article Hepatology · May 2006 Hepatic progenitor cells (called oval cells in rodents) proliferate during chronic liver injury. They have been suggested as targets of malignant transformation in chronic liver diseases, including chronic hepatitis C. Interferon alpha therapy reduces the ... Full text Link to item Cite

Diagnosis and treatment of chronic hepatitis C infection.

Journal Article BMJ · April 29, 2006 Full text Link to item Cite

HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C.

Journal Article Hepatology · February 2006 Patients infected with HIV-1 who are heterozygous at HLA class I loci present greater variety of antigenic peptides to CD8+ cytotoxic T lymphocytes, slowing progression to AIDS. A similar broad immune response in chronic hepatitis C (CHC) infection could r ... Full text Link to item Cite

Kinetics of hepatitis C virus reinfection after liver transplantation.

Journal Article Liver Transpl · February 2006 Improved understanding of hepatitis C virus (HCV) dynamics during and after liver transplantation can be useful in optimizing antiviral therapy in transplant recipients. We analyzed serum HCV ribonucleic acid (RNA) levels during and after cadaveric liver t ... Full text Link to item Cite

The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.

Journal Article J Hepatol · February 2006 Full text Link to item Cite

Clinical Utility of Biomarkers of Liver Fibrosis.

Journal Article Gastroenterol Hepatol (N Y) · January 2006 Hepatic fibrogenesis is a dynamic process and reflects a balance between matrix synthesis and degradation. An accurate determination of hepatic fibrosis in chronic liver disease is important in determining prognosis, therapy outcomes, and disease progressi ... Link to item Cite

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.

Journal Article J Hepatol · January 2006 BACKGROUND/AIMS: ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell cultu ... Full text Link to item Cite

Steatosis and chronic hepatitis C virus infection: mechanisms and significance.

Journal Article Clin Liver Dis · August 2005 Chronic hepatitis C (CHC) and steatosis are common entities that have the potential to interact synergistically and result in significant morbidity. Steatosis is frequently observed in CHC and seems to have a significant impact on the natural history of th ... Full text Link to item Cite

Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection.

Journal Article Transplantation · July 15, 2005 BACKGROUND: Chronic hepatitis C virus (HCV) infection is the most common indication for orthotopic liver transplantation (OLT) in the United States. Recent studies from selected centers have suggested that older donor age is associated with worse outcomes ... Full text Link to item Cite

Treatment of acute hepatitis C infection: more pieces of the puzzle?

Journal Article J Hepatol · March 2005 Full text Link to item Cite

Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin.

Journal Article Am J Gastroenterol · February 2005 OBJECTIVES: The aims of this study were to determine the effect of pretreatment hepatic iron concentration (HIC) on response to combination therapy with interferon and ribavirin, and to examine the change in HIC associated with this treatment. METHODS: Pat ... Full text Link to item Cite

The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA.

Journal Article Antivir Ther · 2005 BACKGROUND: Measuring hepatitis C virus (HCV) RNA in serum or plasma may underestimate the true HCV burden. Extracting viral RNA from whole blood (WB) with a cationic surfactant (Catrimox-14) has resulted in HCV RNA concentrations up to 1000-fold higher th ... Link to item Cite

Tinkering and tailoring with HCV therapy: can we get away with less?

Journal Article Hepatology · December 2004 Full text Link to item Cite

Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.

Journal Article J Hepatol · December 2004 BACKGROUND/AIMS: In chronic hepatitis C (CHC) infection, a liver biopsy provides important information that guides treatment decisions, but is invasive, expensive and associated with possible complications. Extracellular matrix remodeling proteins may be u ... Full text Link to item Cite

Hepatitis C and steatosis.

Journal Article Clin Liver Dis · November 2004 Steatosis is a common finding in patients with chronic hepatitis C (CHC) due to a combination of the direct steatogenic effect of hepatitis C virus (HCV) and the prevalence of metabolic risk factors in the HCV population. Steatosis is now established as a ... Full text Link to item Cite

Current therapies for chronic hepatitis C

Journal Article SENDROM · July 1, 2004 Treatment options for chronic HCV infection have evolved significantly over the last few years, and current therapy with pegylated interferon and ribavirin is effective in 50% to 60% of patients with previously untreated infection. Although there is some e ... Cite

Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.

Journal Article Cleve Clin J Med · May 2004 The main treatment goal in patients with chronic hepatitis C virus (HCV) infection is the prevention of progressive hepatic fibrosis by eradicating serum and intrahepatic virus. The current standard of care in previously untreated patients with chronic hep ... Full text Link to item Cite

Population-based hepatitis C surveillance and treatment in a national managed care organization.

Journal Article Am J Manag Care · April 2004 OBJECTIVES: To use a national population-based automated claims database to study the testing rate, prevalence, and prescribing patterns for chronic hepatitis C. STUDY DESIGN: A retrospective descriptive study that analyzes medical and pharmacy automated c ... Link to item Cite

Risks of a range of alcohol intake on hepatitis C-related fibrosis.

Journal Article Hepatology · March 2004 Heavy alcohol use contributes to liver disease in the setting of chronic hepatitis C virus (HCV) infection. Whether this is true for light or moderate alcohol use has not been demonstrated. Light alcohol use has survival benefits at a population level and ... Full text Link to item Cite

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.

Journal Article J Hepatol · March 2004 BACKGROUND/AIMS: Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes. METHODS: We evaluated liver biopsies from 574 patients with chronic hepatitis C from a single center. RESULT ... Full text Link to item Cite

New therapies for chronic hepatitis C virus infection.

Journal Article Curr Gastroenterol Rep · February 2004 Chronic hepatitis C infection is associated with significant morbidity and mortality in addition to substantial social and health-related costs. Since the identification of the virus and determination of the HCV genome over a decade ago, considerable progr ... Full text Link to item Cite

Current therapies for chronic hepatitis C

Journal Article SENDROM · 2004 Treatment options for chronic HCV infection have evolved significantly over the last few years, and current therapy with pegylated interferon and ribavirin is effective in 50% to 60% of patients with previously untreated infection. Although there is some e ... Cite

Future treatment of hepatitis C: What's around the corner

Journal Article Infections in Medicine · January 1, 2004 Current therapies for the treatment of chronic hepatitis C are effective in only 50% of patients, are associated with side effects, and are not suited for all patients. Advances in understanding the replication cycle and structural components of the virus ... Cite

Selective decontamination of digestive tract in intensive care.

Journal Article Lancet · December 20, 2003 Full text Link to item Cite

Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions.

Journal Article Am J Gastroenterol · November 2003 Full text Link to item Cite

Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?

Journal Article Hepatology · July 2003 Full text Link to item Cite

Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.

Journal Article Postgrad Med · July 2003 Treatment options for chronic HCV infection have evolved significantly over the last few years, and current therapy with pegylated interferon and ribavirin is effective in 50% to 60% of patients with previously untreated infection. Although there is some e ... Full text Link to item Cite

A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy.

Journal Article Hepatology · June 2003 Recombinant human interleukin 12 (IL-12) is an immunomodulatory cytokine that is active against several viruses. Treatment options in patients with chronic hepatitis C with nonresponse to interferon (IFN)-based therapy are limited. Prior dose-ranging studi ... Full text Link to item Cite

Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients.

Journal Article Hepatology · May 2003 Full text Link to item Cite

Noninvasive prediction of fibrosis in patients with chronic hepatitis C.

Journal Article Hepatology · May 2003 Full text Link to item Cite

A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats.

Journal Article Am J Gastroenterol · May 2003 Full text Link to item Cite

Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.

Journal Article J Gastroenterol Hepatol · March 2003 BACKGROUND AND AIM: Hyaluronic acid (HA) is a glycosaminoglycan synthesized by hepatic stellate cells that has been shown to correlate with liver fibrosis in chronic hepatitis C (HCV) patients. However, its use in monitoring fibrosis over time has not been ... Full text Link to item Cite

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.

Journal Article J Viral Hepat · January 2003 The response to antiviral therapy and the rate of fibrosis progression in chronic hepatitis C virus (HCV) infection are related to common factors, including age and gender. The aim of this study was to evaluate the relationship between the rate of fibrosis ... Full text Link to item Cite

Future therapy of hepatitis C.

Journal Article Hepatology · November 2002 Currently available therapies for the treatment of chronic hepatitis C are effective in half of patients, but are expensive, often poorly tolerated, and unsuitable for certain patient populations. The ideal therapy would be highly effective, orally bioavai ... Full text Link to item Cite

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Journal Article Gastroenterology · October 2002 BACKGROUND & AIMS: Patient adherence to prescribed antiviral therapy in human immunodeficiency virus infection enhances response. We evaluated the impact of adherence to combination therapy with interferon or peginterferon plus ribavirin in chronic hepatit ... Full text Link to item Cite

A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection.

Journal Article Genes Immun · September 2002 The hepatitis C virus (HCV) is a major cause of liver disease and the complications of cirrhosis. Liver biopsies, performed prior to the development of liver cirrhosis, characteristically show an inflammatory cell infiltrate with varying degrees of fibrosi ... Full text Link to item Cite

Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

Journal Article Hepatology · July 2002 Hepatitis C virus (HCV) RNA detection, viral load quantification, and HCV genotyping are widely used in clinical practice. Recently, the availability of an anticore antigen (Ag) monoclonal antibody allowed development of an enzyme-linked immunosorbent assa ... Full text Link to item Cite

Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection.

Journal Article J Interferon Cytokine Res · April 2002 In patients with chronic hepatitis C, prior studies have suggested that increased hepatic iron concentration (HIC) is predictive of a poor response to interferon (IFN) monotherapy. The aim of this study was to assess the importance of HIC on the virologic ... Full text Link to item Cite

Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.

Journal Article Hepatology · March 2002 The clinical use of measuring hepatic hepatitis C virus (HCV) RNA before and after therapy in patients with chronic hepatitis C has been assessed in a number of small clinical trials. Viral clearance from the liver may be a better marker of long-term respo ... Full text Link to item Cite

The anatomical distribution of colorectal polyps at colonoscopy.

Journal Article J Clin Gastroenterol · September 2001 BACKGROUND: Colorectal carcinoma is one of the most common causes of cancer-related deaths in Australia. The distribution of polyps in the colon may effect the efficacy of a screening modality. The aim of this study was to determine the age-matched anatomi ... Full text Link to item Cite

Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients.

Journal Article Expert Opin Pharmacother · August 2001 Chronic hepatitis C infection affects approximately four million Americans. Over the last decade, Type 1 interferons (IFNs) have been the mainstay of therapy for suitable patients. Recently, the combination of IFN plus ribavirin, with enhanced response rat ... Full text Link to item Cite

Perioperative management of a common disorder: Hereditary haemochromatosis

Journal Article Current Opinion in Anaesthesiology · January 1, 2000 Hereditary haemochromatosis is the commonest autosomal recessive disorder affecting Caucasian populations, and is readily diagnosed on the basis of elevated total body iron stores and genetic testing. Increased awareness of this disease in the community wi ... Full text Cite

Nonalcoholic Fatty Liver Disease

Journal Article Karnataka Medical Journal Cite